

# Roberta Rud

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1980625/roberta-ruda-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144 papers	4,558 citations	35 h-index	66 g-index
151 ext. papers	5,962 ext. citations	4.6 avg, IF	5.53 L-index

#	Paper	IF	Citations
144	Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members.. <i>Neuro-Oncology Practice</i> , <b>2022</b> , 9, 105-113	2.2	0
143	Ependymoma: Evaluation and Management Updates.. <i>Current Oncology Reports</i> , <b>2022</b> , 1	6.3	0
142	Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study. <i>Cancers</i> , <b>2022</b> , 14, 2425	6.6	
141	Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
140	Systemic Therapy for Lung Cancer Brain Metastases. <i>Current Treatment Options in Oncology</i> , <b>2021</b> , 22, 110	5.4	1
139	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1100-1112	1	17
138	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , <b>2021</b> , 141, 945-957	14.3	9
137	Subependymal Giant Cell Astrocytomas (SEGAs): a Model of Targeting Tumor Growth and Epilepsy. <i>Current Treatment Options in Neurology</i> , <b>2021</b> , 23, 1	4.4	
136	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1547-1559	1	7
135	Prognostic factors in leptomeningeal metastases. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1208-1209	1	
134	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , <b>2021</b> , 22, 813-823	21.7	24
133	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 264-276	1	17
132	Medulloblastoma of the adult: results from a multicenter retrospective study by AINO (Italian Association of Neuro-Oncology) and SIN (Italian Society of Neurology). <i>Neurological Sciences</i> , <b>2021</b> , 42, 665-671	3.5	2
131	Adult brainstem glioma: a multicentre retrospective analysis of 47 Italian patients. <i>Neurological Sciences</i> , <b>2021</b> , 42, 1879-1886	3.5	0
130	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 170-186	19.4	204
129	Evidence-based approaches to chemotherapy for gliomas <b>2021</b> , 38-52		
128	Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasible? Results from AINO study (Italian Association for Neuro-Oncology). <i>Journal of Neurology</i> , <b>2021</b> , 268, 2866-2875	5.5	0

127	Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). <i>European Journal of Cancer</i> , <b>2021</b> , 155, 179-190	7.5	4
126	Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?. <i>Current Opinion in Neurology</i> , <b>2020</b> , 33, 707-715	7.1	2
125	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4478-4484	12.9	5
124	Epilepsy in brain metastasis: an emerging entity. <i>Current Treatment Options in Neurology</i> , <b>2020</b> , 22, 6	4.4	9
123	Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	28
122	Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. <i>Neuro-Oncology Practice</i> , <b>2020</b> , 7, 249-259	2.2	
121	A survey on clinical pathways of patients with epilepsy and cerebrovascular diseases or brain tumors. <i>Neurological Sciences</i> , <b>2020</b> , 41, 1507-1511	3.5	1
120	Long-term survival of a sacro-coccygeal myxopapillary ependymoma with extra-neural metastases: case report and review of the literature. <i>Neurological Sciences</i> , <b>2020</b> , 41, 1955-1957	3.5	
119	Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES). <i>Epilepsia</i> , <b>2020</b> , 61, 647-656	6.4	15
118	NIMG-53. GLUTAMATE/GABA RATIO ON MRS IS ELEVATED IN PATIENTS WITH LOWER GRADE GLIOMAS AND SEIZURES. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii159-ii160	1	
117	NCOG-02. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii129-ii129	1	1
116	SURG-10. PROGNOSTIC IMPORTANCE OF THE EXTENT OF RESECTION IN IDH-WILD TYPE GRADE II ASTROCYTOMAS ACCORDING TO PTERT MUTATION. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii205-ii205	1	
115	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. <i>Journal of Neurosurgical Sciences</i> , <b>2020</b> , 64, 313-334	1.3	11
114	Epilepsy in CNS Metastases <b>2020</b> , 117-125		
113	Prevention Strategies for Brain Metastasis <b>2020</b> , 397-406		
112	Depatuxizumab mafodotin (Depatux-M) plus temozolomide (TMZ) in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2544-2544	2.2	2
111	Does an optimal management of brain metastases from oncogenic-driver non-small cell lung cancer exist?. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 171-172	1	
110	41. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, ii7-ii8	0.9	78

109	Current clinical management of elderly patients with glioma. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 1037-1048	3.5	1
108	Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
107	Management of Brain and Leptomeningeal Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
106	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 996	5.3	4
105	Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , <b>2020</b> , 16, 557-574	15	44
104	Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1610-1611	1	5
103	Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 145, 115-123	4.8	12
102	Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors. <i>Neurology</i> , <b>2019</b> , 93, 217-219	6.5	2
101	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 571-584	1	67
100	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 648-658	1	50
99	Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors. <i>World Neurosurgery</i> , <b>2019</b> , 126, e270-e280	2.1	8
98	New developments and new dilemmas in lower-grade gliomas. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 828-829	1	2
97	Clinical Concepts of Brain Tumors <b>2019</b> , 37-51		
96	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2045-2045	2.2	2
95	Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2019</b> , 78, 248-256	3.1	8
94	Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. <i>Journal of Neurosurgery</i> , <b>2019</b> , 132, 1692-1705	3.2	18
93	Validation and revision of the RANO Leptomeningeal Metastasis Group scorecard for response assessment.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e13546-e13546	2.2	
92	Strategies to prevent brain metastasis. <i>Current Opinion in Oncology</i> , <b>2019</b> , 31, 493-500	4.2	3

91	Intracranial Meningiomas: A Systematic Analysis of Prognostic Factors for Recurrence in a Large Single Institution Surgical Series. <i>World Neurosurgery</i> , <b>2019</b> , 123, e273-e279	2.1	5
90	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 110-119	21.7	116
89	Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. <i>Progress in Neurological Surgery</i> , <b>2018</b> , 31, 168-179	1.4	0
88	Extent of surgery in low-grade gliomas: an old question in a new context. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 6-7	1	5
87	EANO guidelines for the diagnosis and treatment of ependymal tumors. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 445-456	456	100
86	Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 1756286418759618	6.6	13
85	Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 136, 105-114	4.8	20
84	Brain Metastasis as Complication of Systemic Cancers <b>2018</b> , 57-79		
83	Neuro-oncology perspective of treatment options in metastatic breast cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 1765-1774	3.6	3
82	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 161	5.3	72
81	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2047-2047	2.2	3
80	Successful use of bevacizumab in an adult primary diffuse leptomeningeal glioneuronal tumor. <i>Journal of Neurosurgical Sciences</i> , <b>2018</b> , 62, 229-232	1.3	5
79	Overview on current treatment standards in high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 62, 225-238	1.4	9
78	IDH-wild type low grade gliomas: An AINO (Italian Association of Neuro-Oncology) retrospective study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2050-2050	2.2	
77	Spinal melanocytoma with leptomeningeal spread and long survival following surgery and chemotherapy. <i>Journal of Neurosurgical Sciences</i> , <b>2018</b> , 62, 375-378	1.3	0
76	Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Delayed Administration. <i>Anticancer Research</i> , <b>2018</b> , 38, 5877-5881	2.3	6
75	Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. <i>PLoS ONE</i> , <b>2018</b> , 13, e0203570	3.7	9
74	Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2018</b> , 41, 1272-1275	2.7	2

73	Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment. <i>Acta Neurochirurgica</i> , <b>2018</b> , 160, 1779-1787	3	12
72	What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas?. <i>Current Treatment Options in Neurology</i> , <b>2018</b> , 20, 33	4.4	5
71	Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 1155-1164	8.8	58
70	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , <b>2017</b> , 19, 162-174	1	244
69	Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 133, 419-427	4.8	38
68	Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 451-453	1	10
67	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , <b>2017</b> , 390, 1645-1653	4.0	225
66	Imaging and clinical end points in brain metastases trials. <i>CNS Oncology</i> , <b>2017</b> , 6, 243-246	4	4
65	European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e330-e340	21.7	138
64	Controversies in management of low-grade gliomas in light of new data from clinical trials. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 143-144	1	8
63	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 12-21	1	65
62	REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS2085-TPS2085	2.2	3
61	Natural History and Spontaneous Prognostic Factors <b>2017</b> , 307-322		
60	A phase II trial of temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: An AINO (Italian Association for Neuro-Oncology) study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2026-2026	2.2	
59	Leptomeningeal metastases: a RANO proposal for response criteria. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 484-492	1	101
58	Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps. <i>European Radiology</i> , <b>2016</b> , 26, 1263-73	8	19
57	Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 261-8	1	25
56	Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. <i>Neurological Sciences</i> , <b>2016</b> , 37, 2019-2023	3.5	1

55 Spinal epidural metastases **2016**, 596-598

54	Treatment of brain metastasis: current status and future directions. <i>Current Opinion in Oncology</i> , <b>2016</b> , 28, 502-510	4.2	9
53	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 744-51	1	46
52	Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis?. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 12-5	1	6
51	Rare glial tumors. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2016</b> , 134, 399-415	5	10
50	Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 127, 201-3	4.8	3
49	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 401-7	1	41
48	Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. <i>Oncotarget</i> , <b>2016</b> , 7, 21190-8	3.3	15
47	Does the duration of adjuvant temozolomide impact survival in glioblastoma patients? A retrospective analysis from an Italian registry (GLIOSTRY).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2047-2047	2	27
46	BMET-18. DIAGNOSIS AND TREATMENT PATTERNS FOR PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS ACROSS EUROPE. <i>Neuro-Oncology</i> , <b>2016</b> , 18, vi30-vi30	1	
45	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology, the</i> , <b>2016</b> , 3, e217-27	14.6	288
44	Does an optimum treatment for high-risk low-grade gliomas exist?. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1467-1469	14.6	288
43	Molecularly based management of gliomas in clinical practice. <i>Neurological Sciences</i> , <b>2015</b> , 36, 1551-7	3.5	4
42	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e322-32	21.7	247
41	What is New in the Management of Epilepsy in Gliomas?. <i>Current Treatment Options in Neurology</i> , <b>2015</b> , 17, 351	4.4	27
40	Meningiomas after cranial radiotherapy for childhood cancer: a single institution experience. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2015</b> , 141, 1277-82	4.9	12
39	Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 663-9	1	27
38	Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 125, 359-67	4.8	34



37	Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 121, 225-7	4.8	5
36	EPID-27GLIOSTRY (GLIOBLASTOMA REGISTRY) OF THE AINO (ITALIAN ASSOCIATION OF NEURO-ONCOLOGY): ANALYSIS OF FACTORS INFLUENCING SURVIVAL IN GLIOBLASTOMA PATIENTS RECEIVING THE NITROSOUREA FOTEMUSTINE AT FIRST PROGRESSION FOLLOWING THE STUPP REGIMEN. <i>Neuro-Oncology</i> , <b>2015</b> , 17, v84.1-v84	1	78
35	Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients. <i>BMC Cancer</i> , <b>2015</b> , 15, 1021	4.8	12
34	Response to combined radiotherapy and chemotherapy of a leptomeningeal spread from choroid plexus carcinoma: case report. <i>Neurological Sciences</i> , <b>2015</b> , 36, 639-41	3.5	5
33	Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e13003-e13003	2.2	
32	GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2054-2054	2.2	
31	Is there a Role for Bevacizumab in Non-Glial Tumors?. <i>Current Drug Targets</i> , <b>2015</b> , 16, 684-8	3	
30	MGMT promoter methylation in plasma of glioma patients receiving temozolomide. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 117, 347-57	4.8	38
29	Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 116, 533-41	4.8	58
28	Neurologic complications of chemotherapy and other newer and experimental approaches. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2014</b> , 121, 1199-218	3	38
27	Gliomatosis cerebri: a review. <i>Current Treatment Options in Neurology</i> , <b>2014</b> , 16, 273	4.4	20
26	Pharmacologic therapies for malignant glioma: a guide for clinicians. <i>CNS Drugs</i> , <b>2014</b> , 28, 1127-37	6.7	9
25	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 1176-85	1	116
24	Antiangiogenic therapy of brain tumors: the role of bevacizumab. <i>Neurological Sciences</i> , <b>2014</b> , 35, 507-14	3.5	9
23	Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 1739-49	1	60
22	Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e394-7	2.2	1
21	Natural History and Spontaneous Prognostic Factors <b>2013</b> , 265-275		2
20	Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 106, 353-66	4.8	82



19	Malignant spinal cord compression in cerebral glioblastoma multiforme: a multicenter case series and review of the literature. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 110, 221-6	4.8	19
18	Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. <i>Neuro-Oncology</i> , <b>2012</b> , 14 Suppl 4, iv55-64	1	162
17	Low-grade gliomas. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 105, 437-50		12
16	Ependymomas, neuronal and mixed neuronal-glial tumors, dysembroblastic neuroepithelial tumors, pleomorphic xanthoastrocytomas, and pilocytic astrocytomas. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 105, 551-67	3	1
15	Targeted therapy in brain metastasis. <i>Current Opinion in Oncology</i> , <b>2012</b> , 24, 679-86	4.2	61
14	Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2037-2037	2.2	3
13	Epilepsy and brain tumors. <i>Current Opinion in Oncology</i> , <b>2010</b> , 22, 611-20	4.2	118
12	Ependymomas in adults. <i>Current Neurology and Neuroscience Reports</i> , <b>2010</b> , 10, 240-7	6.6	106
11	Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. <i>Journal of Neuro-Oncology</i> , <b>2010</b> , 97, 439-44	4.8	6
10	Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2009</b> , 68, 425-31	3.1	16
9	Neuro-oncology: new insights and advances in treatment. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 14-6	24.1	3
8	Brain metastases: current management and new developments. <i>Current Opinion in Oncology</i> , <b>2008</b> , 20, 676-84	4.2	116
7	Ependymomas of the adult: molecular biology and treatment. <i>Current Opinion in Neurology</i> , <b>2008</b> , 21, 754-61	7.1	68
6	New developments in the treatment of malignant gliomas. <i>Expert Review of Neurotherapeutics</i> , <b>2007</b> , 7, 1313-26	4.3	17
5	New chemotherapy options for the treatment of malignant gliomas. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 621-32	2.4	15
4	Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. <i>Cancer</i> , <b>2004</b> , 100, 807-13	6.4	33
3	Management of brain metastases. <i>Journal of Neurology</i> , <b>2002</b> , 249, 1357-69	5.5	277
2	Brain metastases from unknown primary tumour: a prospective study. <i>Journal of Neurology</i> , <b>2001</b> , 248, 394-8	5.5	55

- 1 PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. *Neurosurgery*, **1998**, 43, 1066-73 3.2 142